StreetAlpha.app
Home › Stocks › CTMX

CytomX Therapeutics, Inc. (CTMX)

Healthcare
$2.03
▼ −0.98%
LAST CLOSE · NOV 20

CytomX Therapeutics develops cancer treatments using its PROBODY masked biologics platform. It last closed at $2.03 on Nov 20, down 0.98% on the day. The next earnings report for CTMX is expected around Mon, Mar 15, 2027. Over its last 8 reports the stock moved an average of 11.5% the session after earnings. Over the last 12 months CTMX insiders bought $0 of stock on the open market and sold $1.2M, according to SEC Form 4 filings.

AI Auto Pilots
Is CTMX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CTMX.

Key Stats

Last 12 months
Results
Revenue
$14.0M
−87.7% vs a year ago
Net income
−$85.4M
−404.9% vs a year ago
Free cash flow
−$51.0M
−363.6% margin
Operating margin
−676.4%
−$94.9M operating income
Valuation
Market cap
$442.5M
218.0M shares
P/E
–
Price to sales
31.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$34.0M
At Sep 30
Shareholder equity
$284.9M
Shares outstanding
218.0M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $37.3M$37.3MFY2021FY2022: $53.2M$53.2MFY2022FY2023: $101.2M$101.2MFY2023FY2024: $138.1M$138.1MFY2024FY2025: $76.2M$76.2MFY2025

From CTMX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 15
Estimated date · Time not announced
Reported EPS
—
Quarter ended Sep 2026
Year ago EPS
—
Same quarter last year
Revenue
$1.7M
−71.7% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Dec 2024: $38.1MDec '24Mar 2025: $50.9MMar '25Jun 2025: $18.7MJun '25Sep 2025: $6.0MSep '25Dec 2025: $663,000Dec '25Mar 2026: $10.3MMar '26Jun 2026: $1.4MJun '26Sep 2026: $1.7MSep '26Latest $1.7M
How CTMX moved after its last 8 reports
Average move the session after a report ±11.5%
Nov 5, 2026After the close+2.3%
Aug 6, 2026After the close+2.7%
May 7, 2026After the close−0.5%
Mar 16, 2026Time not announced+44.2%
Nov 6, 2025After the close−13.6%
Aug 7, 2025After the close+11.9%
Mar 6, 2025After the close+7.7%
Nov 7, 2024After the close+9.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CTMXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CTMX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CTMX

Technical Analysis

CTMX · as of the Nov 20 close · updated each morning
Downtrend

The stock is 5% below its 20 day and 19% below its 50 day average. It is 78% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 42). The nearest support is the Pivot S1 at $1.94, and the nearest resistance the Pivot at $2.05.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 8.8%/day
Key levels
$8.2152 week high+304.4%
$3.61200 day average+77.8%
$2.94100 day average+44.8%
$2.42Swing high (Oct 29)+19.2%
$2.4150 day average+18.7%
$2.14Pivot R1+5.4%
$2.1320 day average+4.9%
$2.05Pivot+1.0%
$2.03Last close
$1.94Pivot S1−4.4%
$1.90Swing low (Nov 10)−6.4%
$1.8752 week low−7.9%
Indicators
RSI (14)42.41Middle of its rangeNeutral
MACD-0.14Above its signal lineBullish
Stochastic23.1Middle of its rangeNeutral
ADX (14)21.7Weak trend
Williams %R-67.3Oversold below −80, overbought above −20Neutral
CCI (20)-49.9Oversold below −100, overbought above 100Neutral
Rate of change−7.3%Change over 10 sessionsBearish
ATR (14)$0.18Typical daily range, 8.8% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CTMX

What happened before

See how CTMX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CTMX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CTMX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CTMXHow many large options trades hit CTMX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

CTMX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲107 buying vs 64 selling
  • ▲Held by funds +1.3 pts
  • ▲Funds holding +15
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding194179+8.4%
In funds' top 1002−100.0%
Held by funds99.2%97.9%+1.3 pts
New / increased39 / 6845 / 72−8.5%
Reduced / sold out41 / 2333 / 46−19.0%
Put/call ratio1.730.56+208.7%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CTMX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CTMX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$1.2M5 sales · 4 insiders
62% of the selling was under pre-arranged trading plans.
2026-03 sold $1.2M2026-06 sold $5KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 15Christopher OgdenCFOSale1,624$3.05$5K
Mar 17Christopher OgdenCFOSale19,323$6.42$124K
Mar 17Marcia BelvinSVP, Chief Scientific OfficerSale31,492$6.42$202K
Mar 17Sean A. McCarthyCEOSale plan118,969$6.42$764K
Mar 17Yu-Waye ChuChief Medical OfficerSale21,279$6.42$137K
Nov 6, 2025Sean A. McCarthyCEOSale plan101,793$4.54$462K
Every insider buy and sale for CTMX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CTMX insider trades →

From SEC Form 4 filings by CTMX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CTMX is in one of them and how their past CTMX trades turned out.

CTMX in the AI portfolios
Loading…

CTMX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CTMX in an article yet. Here's the latest on the wider market.

CTMX in the news

About CytomX Therapeutics

CytomX Therapeutics is a biopharmaceutical company based in South San Francisco, California, that develops cancer treatments. It uses its PROBODY platform to build masked biologic therapies, which are designed to bind more selectively within tumors and limit effects on healthy tissue. Its most advanced candidate, Varsetatug Masetecan, is an antibody drug conjugate being studied in colorectal cancer, with plans to test it in other solid tumors. The company's therapies are aimed at cancer patients.

Headquarters
South San Francisco, CA